1
|
Zhao M, Zhou D, Zhang M, Kang P, Cui M, Zhu L, Luo L. Characteristic of persistent human papillomavirus infection in women worldwide: a meta-analysis. PeerJ 2023; 11:e16247. [PMID: 38025679 PMCID: PMC10655709 DOI: 10.7717/peerj.16247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 09/14/2023] [Indexed: 12/01/2023] Open
Abstract
Objectives We aimed to estimate the genotype distribution of persistent human papillomavirus (HPV) infection in females worldwide, and provided a scientific basis for the prevention strategies of cervical cancer (CC) and the development of HPV vaccines. Methods Both English and Chinese databases were researched from the inception to July 2023. The pooled persistent HPV infection prevalence was calculated using a random effects model. The subgroup analysis was performed to explore the heterogeneity. Publication bias was evaluated using funnel plot, Egger's and Begg's test. Results Twenty-eight studies with 27,335 participants were included. The pooled prevalence of persistent HPV infection was 29.37% (95% CI [24.05%∼35.31%]), and the genotypes with the persistent infection prevalence were HPV16 (35.01%), HPV52 (28.19%), HPV58 (27.06%), HPV18 (25.99%), HPV33 (24.37%), HPV31 (23.35%), HPV59 (21.87%), HPV39 (19.54%), HPV68 (16.61%) and HPV45 (15.05%). The prevalence of multiple and single HPV persistent infection were 48.66% and 36.71%, respectively; the prevalence of persistent HPV infection in different age groups (<30, 30∼39, 40∼49, >50) were 29.83%, 28.39%, 22.24% and 30.22%, respectively. The follow-up time was significantly associated with heterogeneity by subgroup analysis (P < 0.05), and the prevalence of persistent infection decreased with longer follow-up time. Conclusions Multiple infections were more likely to occur persistent HPV infection than single infection. In addition to HPV vaccination, we should emphasize the follow-up management for women under 30 and over 50 years old, those with high-risk HPV infection (HPV59, 39, 68) and multiple infections.
Collapse
Affiliation(s)
- Ming Zhao
- School of Public Health, Jiamusi University, Jiamusi, Heilongjiang, China
- Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China
| | - Dan Zhou
- School of Public Health, Jiamusi University, Jiamusi, Heilongjiang, China
- Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China
| | - Min Zhang
- School of Public Health, Jiamusi University, Jiamusi, Heilongjiang, China
- Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China
| | - Peipei Kang
- Shandong Mental Health Center, Shandong University, Jinan, Shandong, China
| | - Meimei Cui
- Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China
- School of Basic Medical, Weifang Medical College, Weifang, Shandong, China
| | - Liling Zhu
- School of Public Health, Jiamusi University, Jiamusi, Heilongjiang, China
| | - Limei Luo
- Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China
| |
Collapse
|
2
|
Dellino M, Cascardi E, Laganà AS, Di Vagno G, Malvasi A, Zaccaro R, Maggipinto K, Cazzato G, Scacco S, Tinelli R, De Luca A, Vinciguerra M, Loizzi V, Daniele A, Cicinelli E, Carriero C, Genco CA, Cormio G, Pinto V. Lactobacillus crispatus M247 oral administration: Is it really an effective strategy in the management of papillomavirus-infected women? Infect Agent Cancer 2022; 17:53. [PMID: 36271433 DOI: 10.1186/s13027-022-00465-9] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Accepted: 09/28/2022] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Recent studies have shown the importance of the microbiota in women's health. Indeed, the persistence of Human Papilloma Virus (HPV)-related lesions in patients with dysbiosis can be the antechamber to cervical cancer. The aim of this study was to evaluate whether long term administration of oral Lactobacillus crispatus can restore eubiosis in women with HPV infections and hence achieve viral clearance. METHODS In total, 160 women affected by HPV infections were enrolled at the Department of Gynecological Obstetrics of "San Paolo" Hospital, Italy between February 2021 and February 2022. The women were randomly assigned to two groups, one in treatment with oral Lactobacillus crispatus M247 (group 1, n = 80) versus the control group, that hence only in follow-up (Group 2, n = 80). RESULTS After a median follow-up of 12 months (range 10-30 months), the likelihood of resolving HPV-related cytological anomalies was higher in patients in treatment with the long term oral probiotic (group 1) versus the group that perfom only follow-up (group 2) (60.5% vs. 41.3%, p = 0.05). Total HPV clearance was shown in 9.3% of patients undergoing only follow-up compared to 15.3% of patients in the group taking long term oral Lactobacillus crispatus M247 (p = 0.34). However, the percentage of HPV-negative patients, assessed with the HPV-DNA test, documented at the end of the study period was not significantly different from the control group. CONCLUSIONS Despite the limitations of our analysis, we found a higher percentage of clearance of PAP-smear abnormalities in patients who took long term oral Lactobacillus crispatus M247 than in the control group. Larger studies are warranted, but we believe that future research should be aimed in this direction. Trial registration This study is retrospectively registered.
Collapse
Affiliation(s)
- Miriam Dellino
- Department of Biomedical Sciences and Human Oncology, Policlinic of Bari, University of Bari, Piazza Aldo Moro, 70100, Bari, Italy. .,Clinic of Obstetrics and Gynecology, "San Paolo" Hospital, ASL Bari, Bari, Italy.
| | - Eliano Cascardi
- Department of Medical Sciences, University of Turin, Turin, Italy.,Pathology Unit, FPO-IRCCS Candiolo Cancer Institute, Candiolo, Italy
| | - Antonio Simone Laganà
- Unit of Gynecologic Oncology, ARNAS "Civico-Di Cristina-Benfratelli", Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127, Palermo, Italy
| | - Giovanni Di Vagno
- Clinic of Obstetrics and Gynecology, "San Paolo" Hospital, ASL Bari, Bari, Italy
| | - Antonio Malvasi
- Department of Biomedical Sciences and Human Oncology, Policlinic of Bari, University of Bari, Piazza Aldo Moro, 70100, Bari, Italy
| | - Rosanna Zaccaro
- Clinic of Obstetrics and Gynecology, "San Paolo" Hospital, ASL Bari, Bari, Italy
| | - Katia Maggipinto
- Clinic of Obstetrics and Gynecology, "San Paolo" Hospital, ASL Bari, Bari, Italy
| | - Gerardo Cazzato
- Department of Emergency and Organ Transplantation, Pathology Section, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124, Bari, Italy
| | - Salvatore Scacco
- Department of Basic Medical Sciences and Neurosciences, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124, Bari, Italy
| | - Raffaele Tinelli
- Department of Obstetrics and Gynecology, "Valle d'Itria" Hospital, Martina Franca, Italy
| | - Alessandro De Luca
- Department of Biomedical Sciences and Human Oncology, Policlinic of Bari, University of Bari, Piazza Aldo Moro, 70100, Bari, Italy
| | - Marina Vinciguerra
- Clinic of Obstetrics and Gynecology, "San Paolo" Hospital, ASL Bari, Bari, Italy
| | - Vera Loizzi
- Gynecologic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", 70121, Bari, Italy
| | - Antonella Daniele
- Institutional BioBank, Experimental Oncology and Biobank Management Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - Ettore Cicinelli
- Department of Biomedical Sciences and Human Oncology, Policlinic of Bari, University of Bari, Piazza Aldo Moro, 70100, Bari, Italy
| | - Carmine Carriero
- Department of Biomedical Sciences and Human Oncology, Policlinic of Bari, University of Bari, Piazza Aldo Moro, 70100, Bari, Italy
| | | | - Gennaro Cormio
- Gynecologic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", 70121, Bari, Italy
| | - Vincenzo Pinto
- Department of Biomedical Sciences and Human Oncology, Policlinic of Bari, University of Bari, Piazza Aldo Moro, 70100, Bari, Italy
| |
Collapse
|
3
|
Pan S, Wei W, Du X, Li Z, Tuo J, Zhang M, Liu Q. Factors associated with persistence and clearance of HPV16/18 among rural Chinese women: a cohort study in Wufeng, Hubei province. Women Health 2022; 62:276-286. [DOI: 10.1080/03630242.2022.2056283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Shuqi Pan
- Department of Epidemiology, School of Public Health, Wuhan University, Wuhan, Hubei, China
| | - Wenshuang Wei
- Department of Epidemiology, School of Public Health, Wuhan University, Wuhan, Hubei, China
| | - Xueying Du
- Shandong Center for Disease Control and Prevention, Jinan, Shandong, China
| | - Zhi Li
- Department of Public Health, University of Massachusetts Amherst, Amherst, Massachusetts, USA
| | - Jiyu Tuo
- Office of Cancer Prevention and Treatment, Institute of Cancer Prevention and Control, Wuhan, China
| | - Min Zhang
- Office of Cancer Prevention and Treatment, Institute of Cancer Prevention and Control, Wuhan, China
| | - Qing Liu
- Department of Epidemiology, School of Public Health, Wuhan University, Wuhan, Hubei, China
| |
Collapse
|
4
|
Kim SY, Hwang KA, Ann JH, Kim JH, Nam JH. Next-generation sequencing for typing human papillomaviruses and predicting multi-infections and their clinical symptoms. Microbiol Immunol 2021; 65:273-278. [PMID: 34133044 DOI: 10.1111/1348-0421.12927] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Revised: 05/29/2021] [Accepted: 06/12/2021] [Indexed: 11/28/2022]
Abstract
Human papillomavirus (HPV) has more than 100 different types, some of which are associated with cancer. The most common example is that of cervical cancer, which is associated with HPV16 and HPV18. Here, we performed next-generation sequencing (NGS) to type 2436 samples obtained from Korean women to elucidate the correlation between multiple infections, virus types, and cytology. NGS revealed that types 58, 56, and 16 were the most common in high-risk (HR) types, whereas types 90, 54, and 81 were the most common in low-risk (LR) types. The incidence of atypical squamous cells of undetermined significance (ASCUS) or high-grade squamous intraepithelial lesion (HSIL) was 11.45% in single-type cases and 27.17% in multiple infections by the two types of HPV. ASCUS or HSIL was 29.79% in only the HR type multiple infections and 29.81% in mixed high- and low-risk types of multiple infections, whereas it was 18.79% in LR type multiple infections (P ≤ 0.0001). Co-infection by LR-HPV and HR-HPV is therefore more likely to cause cell lesions. Collectively, these results show that the higher the incidence of multiple infections, the greater the frequency of cell lesions. Thus, to predict the clinical symptoms, it would be beneficial to confirm the HPV type and multiple infections using NGS, although this could be relatively expensive.
Collapse
Affiliation(s)
- Sang-Yeon Kim
- Department of Medical and Biological Sciences and Department of Biotechnology, The Catholic University of Korea, Bucheon, Korea.,Department of Quality Assurance, SML Genetree, Seoul, Korea
| | - Kyung-A Hwang
- Department of Quality Assurance, SML Genetree, Seoul, Korea
| | - Ji-Hoon Ann
- Department of Quality Assurance, SML Genetree, Seoul, Korea
| | - Ji-Hye Kim
- Department of Medical Nutrition, Graduate School of East-West Medical Science, The Kyung Hee University of Korea, Yongin, Korea
| | - Jae-Hwan Nam
- Department of Medical and Biological Sciences and Department of Biotechnology, The Catholic University of Korea, Bucheon, Korea
| |
Collapse
|
5
|
Alternative New Mono-scaled Quantitative Benefit-Risk Assessment of Human Papillomavirus Vaccine in Japan. Ther Innov Regul Sci 2020; 55:48-55. [PMID: 32572770 DOI: 10.1007/s43441-020-00189-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 06/11/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND The human papillomavirus (HPV) vaccine coverage is very low in Japan since the government suspended the active encouragement of the vaccination. We aimed to conduct a benefit-risk assessment of HPV vaccination and explore different consequent scenarios to identify potential improvements to the current Japanese immunization program. METHODS To calculate social benefit-risk of HPV vaccine, we used the Markov model to represent the natural history of HPV and adverse events (AEs) using disability-adjusted life year (DALY) as the outcome. Benefits and risks were calculated as the sum of negative and positive outcomes corresponding to all preventable diseases and AEs associated with HPV vaccination, respectively. The benefit-risk balance in 2050 was estimated using published data. RESULTS Our model was confirmed by published cervical cancer incidence and mortality rates. The benefit-risk balance in 2050 showed that the most effective scenario was the introduction of 9-valent HPV vaccine targeting female individuals aged 10-29 years for routine vaccination starting in 2020, although there is possibility of increased risks of AEs for the vaccinated age group post resumption of recommendations. CONCLUSION Our benefit-risk assessment of HPV vaccine helped estimate various scenarios pertaining to HPV vaccination and identify the best strategy regarding HPV vaccination. This benefit-risk assessment approach may be used for other vaccines and vaccination programs.
Collapse
|
6
|
Nyasenu YT, Gbeasor-Komlanvi FA, Issa SAR, Ehlan A, Tchankoni MK, Yambiyo BM, Prince-David M, Salou M, Ekouevi DK, Dagnra A. Prevalence of HPV among HIV-negative women of child-bearing age in Lomé, Togo. Future Virol 2019. [DOI: 10.2217/fvl-2019-0146] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Aim: This study aimed to assess the prevalence and the distribution of HPV genotypes among HIV-negative women of child-bearing age in Lomé, Togo. Materials & methods: From April 2014 to September 2015, a cross-sectional study was conducted among HIV-negative women attending gynecological consultation in six health centers in Lomé. Cervical swabs were obtained from 324 women. HPV test was performed using HPV Direct Flow Chip. Results: The prevalence of any type and oncogenic HPV was 9.3 and 8.3%, respectively. A total of 13 different genotypes HPV, high risk (16, 18, 35, 45, 52, 53, 68, 82) and low risk (6, 40, 43, 44/65, 62/81), were found. Conclusion: Findings from this study provide essential insights for planning future public health strategies, including HPV vaccination programs.
Collapse
Affiliation(s)
- Yawo Tufa Nyasenu
- Département des Sciences Fondamentales, Laboratoire de Biologie Moléculaire et d’Immunologie (BIOLIM), Université de Lomé, Lomé, Togo
| | - Fifonsi Adjidossi Gbeasor-Komlanvi
- Département de Santé Publique, Université de Lomé, Lomé, Togo
- Centre Africain de Recherche en Epidémiologie et en Santé Publique, Lomé, Togo
| | - Sabi Abdul-Raouf Issa
- Département des Sciences Fondamentales, Laboratoire de Biologie Moléculaire et d’Immunologie (BIOLIM), Université de Lomé, Lomé, Togo
| | - Amivi Ehlan
- Département des Sciences Fondamentales, Laboratoire de Biologie Moléculaire et d’Immunologie (BIOLIM), Université de Lomé, Lomé, Togo
| | | | - Brice Martial Yambiyo
- Service d’Epidémiologie, Institut Pasteur de Bangui, Bangui, République Centrafricaine
| | - Mireille Prince-David
- Département des Sciences Fondamentales, Laboratoire de Biologie Moléculaire et d’Immunologie (BIOLIM), Université de Lomé, Lomé, Togo
| | - Mounerou Salou
- Département des Sciences Fondamentales, Laboratoire de Biologie Moléculaire et d’Immunologie (BIOLIM), Université de Lomé, Lomé, Togo
| | - Didier Koumavi Ekouevi
- Département de Santé Publique, Université de Lomé, Lomé, Togo
- Centre Africain de Recherche en Epidémiologie et en Santé Publique, Lomé, Togo
- Institut de Santé Publique Epidémiologie Développement (ISPED), Université de Bordeaux, Bordeaux, France
- Centre Inserm, 1219, Université de Bordeaux, Bordeaux, France
| | - Anoumou Dagnra
- Département des Sciences Fondamentales, Laboratoire de Biologie Moléculaire et d’Immunologie (BIOLIM), Université de Lomé, Lomé, Togo
| |
Collapse
|
7
|
Li W, Meng Y, Wang Y, Cheng X, Wang C, Xiao S, Zhang X, Deng Z, Hu M, Shen P, Xu S, Fu C, Jiang W, Wu B, Li K, Chen G, Wei J, Xi L, Hu J, Ma D, Xue M, Xie X, Wu P. Association of age and viral factors with high-risk HPV persistence: A retrospective follow-up study. Gynecol Oncol 2019; 154:345-353. [DOI: 10.1016/j.ygyno.2019.05.026] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Revised: 05/06/2019] [Accepted: 05/28/2019] [Indexed: 01/20/2023]
|